[HT-01] ホットトピックス01

[HT-01-1] Gantenerumab in early symptomatic Alzheimers Disease

Janice W. Smith (Roche Products Ltd)

Janice Smith, Ph.D. is the Global Development Leader of the gantenerumab program in early Alzheimer’s Disease at Roche. During her time at Roche, Janice has focused on drug development in the late-stage neuroscience organization and has led clinical development teams across a number of different indications from digital therapeutics to Autism and Alzheimer’s disease where she has been significantly involved in two programs. Janice joined Roche in 2011 from previous roles at both Grunenthal and Lilly where she worked in psychiatry, neurodegeneration, and pain research.

Janice obtained a degree in pharmacology from the University of Southampton, followed by a PhD in psychopharmacology from the University of Bristol, UK. She undertook post-doctoral research at the University of Cambridge, UK, and the University of Pennsylvania, USA before joining the industry in 2001.